Aclaris Therapeutics, Inc.Pembelian
ACRS Aclaris Therapeutics Potential Buyout
ACRS Aclaris Therapeutics has 3 clinical trials releasing topline data this year and sufficient cash to fund their operations through the end of 2025.
ACRS is in Piper Sandler`s potential 12 biotech takeovers in 2023.
ACRS reached 52 week low today: $5.05.
Analysts Price Targets:
$21 The Goldman Sachs Group
$29 BTIG Research
$38 Cantor Fitzgerald
$43 HC Wainwright
Considering the above, I think ACRS might be an easy +3X!
Looking forward to read your opinion about it.
ACRS is in Piper Sandler`s potential 12 biotech takeovers in 2023.
ACRS reached 52 week low today: $5.05.
Analysts Price Targets:
$21 The Goldman Sachs Group
$29 BTIG Research
$38 Cantor Fitzgerald
$43 HC Wainwright
Considering the above, I think ACRS might be an easy +3X!
Looking forward to read your opinion about it.
Private SIGNALS patreon.com/PremiumOptionsSignals
Trading COURSE bit.ly/tradex
RESULTS bit.ly/topgx
1%/DAY: bit.ly/3F56VTW
CRYPTO partner.bybit.com/b/37880
BUY-SELL INDICATORS tradingindicators.store/
Trading COURSE bit.ly/tradex
RESULTS bit.ly/topgx
1%/DAY: bit.ly/3F56VTW
CRYPTO partner.bybit.com/b/37880
BUY-SELL INDICATORS tradingindicators.store/
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.